.png)
The United States has given its approval to the world’s first twice-a-year injection for HIV prevention, marking a significant step towards a global rollout that could safeguard millions, The Independent reported.The drug, lenacapavir, developed by Gilead Sciences, offers a powerful new option in the fight against the virus, though questions remain regarding its accessibility both within the US and internationally.While the ultimate goal of an HIV vaccine remains elusive, experts are hailing lenacapavir as a groundbreaking alternative.Clinical studies demonstrated its remarkable efficacy, nearly eliminating new infections in high-risk individuals, outperforming daily preventive pills which can be easily forgotten."This really has the possibility of ending HIV transmission," stated Greg Millett, public policy director at amfAR, The Foundation for AIDS Research.Condoms help guard against HIV infection if used properly, but what's called PrEP — regularly using preventive medicines such as the daily pills or a different shot given every two months — is increasingly important.Lenacapavir’s six-month protection period makes it the longest-lasting preventive option available. This extended duration could prove particularly appealing to individuals who are wary of frequent doctor visits or who face stigma associated with daily medication.However,...